(Reuters) – Japan’s Sosei Group Corp will collaborate with AbbVie Inc on a drug discovery partnership that could be worth up to $1 billion. Sosei shares soared 12.4% in Tokyo trading, compared with a 1.2% slide in the broader market. The partnership will initi... More »
(Reuters) – AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition. A fou... More »
(Reuters) – AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to meet the main goal in a late-stage trial. The company’s shares fell 1.8 percent to $78.10 before the b... More »
(Reuters) – A U.S. judge on Thursday overturned a $140.1 million verdict against AbbVie Inc in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack. U.S. Distric... More »
(Reuters) – A U.S. judge on Friday found that pharmaceutical company AbbVie Inc used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 mi... More »
(Reuters) – AbbVie Inc reported a better-than-expected quarterly profit on Thursday, on higher sales of its rheumatoid arthritis treatment Humira and its Hepatitis C drugs, leading the company to raise its full-year earnings forecast. The company’s shares, whi... More »
FILE PHOTO: A trader works by the post that trades AbbVie on the floor of the New York Stock Exchange March 5, 2015. REUTERS/Brendan McDermid (Reuters) – A federal jury in Chicago on Friday found AbbVie Inc (ABBV.N) not liable in a lawsuit by an Arizona man wh... More »
FILE PHOTO — A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014. REUTERS/Brendan McDermid/File Photo (Reuters) – A U.S. judge on Friday overturned a $150 million verdict against AbbVie In... More »
A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, the plaintiff's lawyer said in a statement. More »
FILE PHOTO — A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014. REUTERS/Brendan McDermid/File Photo A federal jury on Friday awarded $15 million to a 10-year-old boy whose mother blamed ... More »
AbbVie Inc said on Wednesday its oral rheumatoid arthritis drug succeeded in a late-stage study on patients who had not adequately responded to standard treatments. More »
A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014. Shire said on July 18 that it had accepted an offer of 32 billion pounds ($54.7 billion) from AbbVie. REUTERS/Brendan McDermid AbbVie I... More »
A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014. REUTERS/Brendan McDermid AbbVie Inc won the conditional backing of an advisory committee of the European Medicines Agency (EMA) on Frid... More »
An experimental once-daily combination hepatitis C treatment being developed by AbbVie Inc demonstrated very high cure rates across a wide range of disease genotypes, according to data presented on Saturday, likely giving the company a more competitive product... More »
SEOUL Samsung Bioepis Co Ltd, which aims to become a force in the fledgling biosimilar drugs industry, has filed a lawsuit against the originator of the world’s best-selling drug, to stop it blocking the launch of its own version. The unit of South Korea’s Sam... More »
